Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Metastatic Gastric Cancer
- Esophageal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of Michigan Rogel Cancer Center
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- University of Michigan Rogel Cancer Center · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.